Antibody-drug conjugates and uses thereof
US11596693B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 23, 2019 |
| Grant date | Mar 7, 2023 |
| Priority date | — |
| Expiry date | Aug 29, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/6889
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an antibody-drug conjugate (ADC) using one or more cysteine or derivatives thereof as linkers to couple one or more drugs at the limited binding sites of an antibody, making it possible to produce an ADC product with high drug payload, or to choose a drug with less toxicity, thereby obtaining an ADC product with wide therapeutic window. In addition, since a plurality of drugs may be coupled to one binding site, the ADC products obtained by the method of the present disclosure have better uniformity in the case of same DAR value. Moreover, the amount of antibody required for production may be greatly reduced, thereby lowering the cost. Compared with the antibody-drug conjugates coupled only one drug, the antibody-drug conjugates produced by the method of the present disclosure have the same inhibition or killing effect on tumor cells while using fewer drugs for coupling to the same site.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.